| Identification |
|---|
| HMDB Protein ID
| HMDBP01564 |
| Secondary Accession Numbers
| |
| Name
| Cytochrome P450 4F8 |
| Synonyms
|
- CYPIVF8
|
| Gene Name
| CYP4F8 |
| Protein Type
| Unknown |
| Biological Properties |
|---|
| General Function
| Secondary metabolites biosynthesis, transport and catabolism |
| Specific Function
| Hydroxylates arachidonic acid (20:4n-6) to (18R)-hydroxyarachidonate. Shows little activity against prostaglandin (PG) D2, PGE1, PGE2, PGF2alpha, and leukotriene B4. Catalyzes omega-2 and omega-3-hydroxylation of PGH1 and PGH2. Catalyzes epoxidation of 4,7,10,13,16,19-(Z)-docosahexaenoic acid (22:6n-3) and 7,10,13,16,19-(Z)-docosapentaenoic acid (22:5n-3) and omega-3-hydroxylation of 4,7,10,13,16-(Z)-docosapentaenoic acid (22:5n-6). Catalyzes hydroxylation of PGI2 and carbaprostacyclin.
|
| Pathways
|
- Acetaminophen Action Pathway
- Acetylsalicylic Acid Action Pathway
- Antipyrine Action Pathway
- Antrafenine Action Pathway
- Arachidonic acid metabolism
- Arachidonic Acid Metabolism
- Bromfenac Action Pathway
- Carprofen Action Pathway
- Celecoxib Action Pathway
- Diclofenac Action Pathway
- Diflunisal Action Pathway
- Etodolac Action Pathway
- Etoricoxib Action Pathway
- Fenoprofen Action Pathway
- Flurbiprofen Action Pathway
- Ibuprofen Action Pathway
- Indomethacin Action Pathway
- Ketoprofen Action Pathway
- Ketorolac Action Pathway
- Leukotriene C4 Synthesis Deficiency
- Lornoxicam Action Pathway
- Lumiracoxib Action Pathway
- Magnesium salicylate Action Pathway
- Mefenamic Acid Action Pathway
- Meloxicam Action Pathway
- Nabumetone Action Pathway
- Naproxen Action Pathway
- Nepafenac Action Pathway
- Oxaprozin Action Pathway
- Phenylbutazone Action Pathway
- Piroxicam Action Pathway
- Rofecoxib Action Pathway
- Salicylate-sodium Action Pathway
- Salicylic Acid Action Pathway
- Salsalate Action Pathway
- Sulindac Action Pathway
- Suprofen Action Pathway
- Tenoxicam Action Pathway
- Tiaprofenic Acid Action Pathway
- Tolmetin Action Pathway
- Trisalicylate-choline Action Pathway
- Valdecoxib Action Pathway
|
| Reactions
|
| RH + reduced flavoprotein + Oxygen → ROH + oxidized flavoprotein + Water |
details
|
| Leukotriene B4 + NADPH + Hydrogen Ion + Oxygen → 20-Hydroxy-leukotriene B4 + NADP + Water |
details
|
| Arachidonic acid + Oxygen + NADPH + Hydrogen Ion → 20-Hydroxyeicosatetraenoic acid + NADP + Water |
details
|
|
| GO Classification
|
| Biological Process |
| prostaglandin metabolic process |
| xenobiotic metabolic process |
| Cellular Component |
| endoplasmic reticulum membrane |
| integral to membrane |
| Function |
| ion binding |
| cation binding |
| metal ion binding |
| binding |
| catalytic activity |
| transition metal ion binding |
| electron carrier activity |
| iron ion binding |
| monooxygenase activity |
| heme binding |
| oxidoreductase activity |
| Molecular Function |
| electron carrier activity |
| aromatase activity |
| iron ion binding |
| heme binding |
| alkane 1-monooxygenase activity |
| Process |
| metabolic process |
| oxidation reduction |
|
| Cellular Location
|
- Endoplasmic reticulum membrane
- Single-pass membrane protein
- Microsome membrane
|
| Gene Properties |
|---|
| Chromosome Location
| 19 |
| Locus
| 19p13.1 |
| SNPs
| CYP4F8 |
| Gene Sequence
|
>1563 bp
ATGTCGCTGCTGAGCCTGTCTTGGCTGGGCCTCAGGCCGGTGGCAGCATCCCCGTGGCTG
CTCCTGCTGGTGGTCGGGGCCTCCTGGCTCCTGGCCCGCATCCTGGCCTGGACCTATGCC
TTCTATCACAACGGCCGCCGCCTCCGGTGTTTCCCGCAGCCCCGGAAACAGAACTGGTTC
TTGGGTCACCTGGGCCTGGTCACTCCCACAGAGGAGGGCTTGAGGGTCCTGACCCAGCTG
GTGGCCACCTACCCCCAGGGCTTTGTGAGGTGGTTGGGCCCCATCACTCCCATCATCAAC
TTGTGCCACCCTGACATCGTCCGATCTGTCATCAATACCTCAGATGCCATTACAGACAAG
GACATAGTCTTCTACAAGACCCTGAAGCCCTGGCTGGGGGATGGGCTCTTGTTAAGTGTT
GGTGACAAGTGGAGACACCACCGTCGCTTGCTGACGCCTGCCTTCCATTTCAACATCCTG
AAGCCCTATATAAAGATTTTCAGCAAGAGTGCAAACATCATGCATGCCAAGTGGCAACGC
CTGGCCATGGAGGGCAGCACCTGTCTGGATGTGTTTGAGCACATCAGCCTTATGACCCTG
GACAGTCTGCAGAAATGCATCTTCAGCTTTGACAGCAATTGTCAGGAGAAGCCCAGTGAA
TATATTACTGCGATCATGGAGCTCAGTGCCCTTGTAGTGAAACGGAATAACCAGTTCTTC
CGGTACAAGGACTTCCTGTACTTCCTCACTCCCTGTGGACGGCGCTTCCACAGGGCCTGC
AGACTGGTGCACGACTTCACAGATGCCGTCATCCAGGAGCGGCGCCGCACCCTCACTAGC
CAGGGTGTTGATGACTTCCTCCAAGCCAAGGCCAAGTCCAAGACTTTGGACTTTATTGAT
GTGCTCCTGCTGAGCGAGGATAAAAATGGTAAAGAGTTGTCAGATGAGGACATAAGAGCA
GAAGCTGACACTTTCATGTTTGGAGGCCATGACACCACGGCCAGTGGCCTCTCCTGGGTC
TTGTACAACCTCGCGAGGCACCCAGAATACCAAGAACGCTGCCGGCAGGAGGTGCAAGAG
CTTCTGAAGGACCGTGAGCCTAAAGAGATTGAATGGGACGACCTGGCCCAGTTGCCCTTC
CTGACCATGTGCCTGAAGGAGAGCCTGCGGTTGCATCCCCCAATCCCTACATTCGCCCGC
GGCTGCACCCAGGACGTGGTGCTCCCAGACAGCCGAGTCATCCCCAAAGGGAATGTCTGT
AACATCAACATCTTCGCAATCCATCACAACCCCTCAGTCTGGCCAGACCCTGAGGTCTAT
GACCCCTTCCGCTTCGACCCCGAAAACGCCCAGAAGAGGTCACCTATGGCTTTTATTCCT
TTCTCGGCGGGGCCCAGGAACTGCATCGGGCAGAAGTTCGCGATGGCAGAGATGAAGGTG
GTCCTGGCGCTCACGCTGCTGCGCTTCCGCATCCTGCCCGACCACAGGGAGCCACGCAGG
ACGCCGGAGATTGTTTTGCGTGCGGAGGACGGACTTTGGCTGCGAGTAGAACCCCTGGGC
TGA
|
| Protein Properties |
|---|
| Number of Residues
| 520 |
| Molecular Weight
| 59993.995 |
| Theoretical pI
| 8.429 |
| Pfam Domain Function
|
|
| Signals
|
Not Available
|
|
Transmembrane Regions
|
Not Available
|
| Protein Sequence
|
>Cytochrome P450 4F8
MSLLSLSWLGLRPVAASPWLLLLVVGASWLLARILAWTYAFYHNGRRLRCFPQPRKQNWF
LGHLGLVTPTEEGLRVLTQLVATYPQGFVRWLGPITPIINLCHPDIVRSVINTSDAITDK
DIVFYKTLKPWLGDGLLLSVGDKWRHHRRLLTPAFHFNILKPYIKIFSKSANIMHAKWQR
LAMEGSTCLDVFEHISLMTLDSLQKCIFSFDSNCQEKPSEYITAIMELSALVVKRNNQFF
RYKDFLYFLTPCGRRFHRACRLVHDFTDAVIQERRRTLTSQGVDDFLQAKAKSKTLDFID
VLLLSEDKNGKELSDEDIRAEADTFMFGGHDTTASGLSWVLYNLARHPEYQERCRQEVQE
LLKDREPKEIEWDDLAQLPFLTMCLKESLRLHPPIPTFARGCTQDVVLPDSRVIPKGNVC
NINIFAIHHNPSVWPDPEVYDPFRFDPENAQKRSPMAFIPFSAGPRNCIGQKFAMAEMKV
VLALTLLRFRILPDHREPRRTPEIVLRAEDGLWLRVEPLG
|
| External Links |
|---|
| GenBank ID Protein
| 5733409 |
| UniProtKB/Swiss-Prot ID
| P98187 |
| UniProtKB/Swiss-Prot Entry Name
| CP4F8_HUMAN |
| PDB IDs
|
Not Available |
| GenBank Gene ID
| AF133298 |
| GeneCard ID
| CYP4F8 |
| GenAtlas ID
| Not Available |
| HGNC ID
| HGNC:2648 |
| References |
|---|
| General References
| - Bylund J, Finnstrom N, Oliw EH: Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. Biochem Biophys Res Commun. 1999 Jul 22;261(1):169-74. [PubMed:10405341 ]
- Bylund J, Hidestrand M, Ingelman-Sundberg M, Oliw EH: Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. J Biol Chem. 2000 Jul 21;275(29):21844-9. [PubMed:10791960 ]
- Stark K, Torma H, Cristea M, Oliw EH: Expression of CYP4F8 (prostaglandin H 19-hydroxylase) in human epithelia and prominent induction in epidermis of psoriatic lesions. Arch Biochem Biophys. 2003 Jan 1;409(1):188-96. [PubMed:12464258 ]
- Stark K, Wongsud B, Burman R, Oliw EH: Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8. Arch Biochem Biophys. 2005 Sep 15;441(2):174-81. [PubMed:16112640 ]
- Stark K, Bylund J, Torma H, Sahlen G, Oliw EH: On the mechanism of biosynthesis of 19-hydroxyprostaglandins of human seminal fluid and expression of cyclooxygenase-2, PGH 19-hydroxylase (CYP4F8) and microsomal PGE synthase-1 in seminal vesicles and vas deferens. Prostaglandins Other Lipid Mediat. 2005 Jan;75(1-4):47-64. [PubMed:15789615 ]
|
